This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): bupropion hydrochloride extended release
Description: Biomedtracker has a separate entry for the immediate and sustained release formulations of Wellbutrin.
Wellbutrin XL is a once-daily formulation of bupropion. Wellbutrin is an antidepressant that inhibits the reuptake of dopamine, norephinephrine, and to some extent serotonin. Its effect on dopamine is the most potent, but in actuality, it is a fairly weak reuptake blocker of all three of these, and its mechanism of action is not clear.
Deal Structure: Wellbutrin was originally developed by Burroughs-Wellcome (which became GSK).
All historical revenue for Wellbutrin is recorded under Wellbutrin/SR.
Biovail and GSK
Biovail developed the once-daily formulation Wellbutrin XL, which they licensed to GSK in October 2001 (global marketing rights except Canada). Biovail supplies the drug and receives a three-tiered supply price. In the lowest tier, Biovail receives a supply price of less than 25% of GSK's net sales price, in the second tier between 25% and 30%, and in the highest tier over 30%.
In May 2009, GlaxoSmithKline announced that it entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories, a subsidiary of Biovail Corporation, for $510 million. Under the terms of the agreement, GSK will transfer the US NDA and license the Wellbutrin XL trademark to Biovail for use in the US. GSK will retain existing rights to Wellbutrin XL (excluding...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Wellbutrin XL News
Additional information available to subscribers only: